Salomon Initiates Coverage of Genaissance with Venture, Buy Rating | GenomeWeb

NEW YORK, Sept 8 – Salomon Smith Barney initiated coverage of Genaissance Pharmaceuticals (Nasdaq: GNSC) with a Venture, Buy rating and issued a 12-month price target of $32 a share.

Genaissance of New Haven, Conn., was trading up 1 1/16, or 4.8 percent, at $23 in late morning trading.

In a report, analyst Meirav Chovav said that the company has shown that its HAP technology platform for identifying gene-specific SNPs can predict a person’s response to a drug or their predisposition to a disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."